Aquestive Therapeutics (AQST) Invested Capital (2017 - 2026)

Aquestive Therapeutics' Invested Capital history runs 10 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Invested Capital rose 117.97% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (up 117.97% YoY), while the FY2025 annual figure was $11.3 million, up 174.81% from the prior year.
• Invested Capital was $10.9 million for Q1 2026 at Aquestive Therapeutics, down from $11.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $11.3 million in Q4 2025 to a low of -$93.6 million in Q3 2022.
• Historically, Invested Capital has averaged -$42.5 million across 5 years, with a median of -$61.5 million in 2023.
• Biggest YoY gain for Invested Capital was 628.1% in 2025; the steepest drop was 829.05% in 2025.
• A 5-year view of Invested Capital shows it stood at -$67.1 million in 2022, then increased by 8.3% to -$61.5 million in 2023, then surged by 75.35% to -$15.2 million in 2024, then soared by 174.81% to $11.3 million in 2025, then decreased by 3.46% to $10.9 million in 2026.
• The last three Invested Capital figures came in at $10.9 million (Q1 2026), $11.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.